Zimbabwe has turned down a significant American healthcare agreement worth $367m (£272m) over five years due to Washington's demand for confidential biological samples.
This rejection became public after a official document from December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "unbalanced".
A government spokesman has since explained that the US was requesting biological samples for research and profit while was not willing to guarantee the benefits from any future medical innovations.
"We are forced to start the challenging and unfortunate process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged continued dialogue to find a agreement agreeable to both sides so the nation's critical HIV programme can continue.
Wider Implications
This rejection comes after a comparable case in Kenya, where a court suspended a similar deal with the US following legal challenges were raised about the security of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had managed assistance for the American government, but Trump claimed its expenditure was "inefficient" and his administration was seeking government-to-government agreements to enhance openness and responsibility.
Based on reports, 16 nations in Africa have to date agreed to these new agreements, constituting over $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe would have supported "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership might have yielded extraordinary advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently on HIV treatment via American-funded programmes," the Ambassador added.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to share its biological resources and data for a long time, with no equivalent promise of access to any scientific breakthroughs – like new medicines or tests – that could result from that shared data," Mangwana explained.
"In essence, our nation would provide the raw materials for medical research without any certainty that the final treatments would be accessible to our citizens should a new pandemic emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral health agreements were undermining systems previously established via the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to manage potential pandemics.
"This mechanism is intended to ensure that when a nation provides its data, the benefits – such as medicines and cures – are shared equitably, not monopolised solely by those with the resources to create them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how subsequent collaboration could be arranged in a manner that honours the sovereignty and dignity of both nations."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the official position, but suggested that negotiations should continue since a large portion of the nation's Aids initiatives depended on international support.
"If technical issues exist, including those involving information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," it commented.
The halted deal highlights the continuing tensions between receiving crucial foreign assistance and safeguarding national sovereignty in an ever more data-driven world.